Bispecifics in Multiple Myeloma: Patient Journey and Clinical Insights

home / from-all-angles / bispecifics-in-multiple-myeloma-patient-journey-and-clinical-insights

Binod Dhakal, MD, MS, and Karen Kehl discuss how bispecific antibody therapy with talquetamab has transformed the treatment journey for a multiple myeloma patient who achieved durable responses after 19-plus prior treatments, exploring the drug's mechanism targeting GPRC5D, clinical trial data showing 70% response rates, practical considerations including step-up dosing strategies and manageable adverse effects like taste changes and nail issues, and the patient's positive quality of life outcomes that have allowed her to continue living actively 16 years post diagnosis.